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  Recently, research has demonstrated potentiation of the dopamine transporter’s 
function by ethanol.  This, coupled with data showing that the modulation of transporter 
uptake is determined by changes in trafficking and not function, implied that ethanol 
increases the number of transporters on the cell surface.  To identify which amino acid 
sites may be targets for ethanol, hybrid transporters were constructed that share different 
ratios of amino acid sequences with the dopamine transporter and the norepinephrine 
transporter, a similar protein that lacks ethanol-mediated potentiation.  Dopamine 
transporter mutants were created at the four most promising amino acid residues using 
site directed mutagenesis.  Two mutants expressed in Xenopus oocytes showed some 
sensitivity to ethanol and two did not.  The quadruple transporter mutant, which contains 
all four amino acid mutations, demonstrated the most interesting phenotype of inability to 
take up dopamine. 
 The present study confirms this lack of function in human embryonic kidney 
(HEK) cells, a mammalian expression system, and addresses whether or not the IGLF 
dopamine transporter is on the surface, yet not functional, or is simply not trafficked to 
the cell surface.  To accomplish this, HEK cells stably expressing the wild-type or 
quadruple mutant transporter were created.  Radioactive uptake assays were used to 
determine the extent to which each cell type was able to take up dopamine.  Cell surface 
biotinylation and Western blots were then used to identify surface transporters  Both 
preliminary results and the current study showed lack of uptake in HEK cells expressing 
the mutant, while the latter determined that the mutant protein was present on the cell 
surface, albeit to a lesser extent than wild-type protein.  By demonstrating that the 
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transporter is indeed being trafficked to the surface, the implication that the mutant is 




 The annual cost of alcohol abuse to society at large has been estimated at 185 
billion dollars (U.S. Department of Health and Human Services, 2000).  Alcohol related 
deaths rank number three, just under tobacco usage and poor diet, on the list of unnatural 
causes of death in the U.S. (Marshall, 2004).  Although the molecular targets of ethanol 
in the central nervous system are widespread and include many of the prominent 
neurotransmitter systems (glycine, GABA, 5-HT), the most interesting, from an addiction 
research perspective, is the dopaminergic circuitry that makes up the reward pathway in 
the brain (Vengeliene, et al, 2008).  Drugs of abuse directly and indirectly change the 
firing patterns, metabolism, and gene expression of neurons in these brain regions, most 
notably the neurons projecting from the ventral tegmental area in the midbrain to the 
nucleus accumbens (the mesolimbic circuit) (Bowirrat and Oscar-Berman, 2005).  These 
actions disrupt the homeostasis of the system and can lead to the aberrant behavioral 
phenotypes seen in addicts.   
 Dopamine is secreted from vesicles by presynaptic dopaminergic neurons onto 
neurons expressing dopamine receptors on their cell surface .  When dopamine is released 
into the space between the two neurons (known as the synaptic cleft), this 
neurotransmitter binds to the postsynaptic receptors.  This can lead to a wide range of 
actions on the postsynaptic cell such as inhibition, excitation, or even changes in gene 
 5
expression (as mediated by more complex signaling cascades).  These effects alter the 
neurons' ability to depolarize and fire, which in turn determines the physiological output 
of the cell.  
 Dopamine signaling is terminated by its removal from the synaptic cleft.  
Otherwise, it would constantly be bound to its postsynaptic receptors, leading to a 
sustained, non-variable signal.  Although some of the neurochemical diffuses away into 
areas where it can no longer act on receptors, the primary means by which dopamine is 
removed from the synapse is via the dopamine transporter (DAT).  This protein tightly 
controls the temporal and spatial activity of dopamine neurotransmission and is 




Figure 1.  Pre- and perisynaptically located monoamine transporters are the primary 
means by which the spatial and temporal activity of dopamine transmission is controlled 
(Torres, et al, 2003). 
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 The dopamine transporter belongs to a family of high-affinity, Na
+
-dependent 
integral membrane proteins that remove monoamines from the cleft (Torres, et al, 2003).  
Norepinephrine and 5-hydroxytryptamine (serotonin) transporters are examples of two 
other members of this family.  The dopamine and norepinephrine transporters can 
transport each other’s substrates (norepinephrine and dopamine, respectively) (Gu, et al, 
1994).  All three transporters are located pre- and perisynaptically, allowing for exquisite 
control over transmission (Fig. 1).  They also all pass through the lipid bilayer twelve 
times (Fig. 2b). 
 Prior research on Xenopus laevis oocytes has shown that DAT function is 
potentiated by ethanol in a concentration-dependent manner, while the function of NET 
(norepinephrine transporter) is inhibited (Mayfield, et al, 2001).  These opposing effects 
and the similarity of the two protein sequences led researchers to create hybrid proteins 
called chimeras in which regions of DAT and NET were combined.  After testing the 
effects of ethanol on these chimeras, a 76-amino acid stretch encompassing the first 
intracellular loop was demonstrated to be necessary for the ethanol effect (Maiya, et al, 
2002).  Only four amino acid residues in this loop lack sequence homology between the 
two transporters, so site directed mutagenesis was used to change each of the four DAT 
residues (glycine 130, isoleucine 137, phenylalanine 123, and leucine 138, with the 
number corresponding to location in the primary protein structure) to their corresponding 
NET residues (threonine, phenylalanine, tyrosine, and phenylalanine respectively).  In 
addition, a quadruple mutant containing all four mutations and dubbed IGLF was created 
and examined.  In  Xenopus oocytes transfected with each of the five cRNA types, it was 
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demonstrated that the G130T and I137F mutants lacked ethanol potentiation, while the 
function of F123Y and L138F showed slight potentiation when compared to wild-type 
transporter.   
 
Figure 2.  Sequence homology of DAT, NET, and SERT and schematic structure for 
members of this transporter family (Torres, et al, 2003).  
 
The quadruple mutant showed no signs of transporter activity in radioactive 
dopamine uptake assays and also showed drastically reduced surface expression, as 
assayed by tritiated WIN 35,428 binding studies.  The latter uses the binding ability of a 
radioactive isotope to determine surface density.  However, these studies were performed 
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in Xenopus oocytes, and it was yet to be determined if the same held for mammalian 
expression systems.  The goal of the current study was to confirm that IGLF DAT was 
nonfunctional and to determine whether or not it was present on the surface of human 
embryonic kidney (HEK 293) cells.    
 
 Materials and Methods: 
Cell culture  
 HEK 293 cells were purchased from ATCC (Manassas, VA).  They were 
maintained in a humidified atmosphere at 37 degrees Celsius and 5% CO
2
 in Dulbecco’s 
Modified Eagle Medium (Gibco, Carlsbad, CA) supplemented with 10% fetal bovine 
serum (Atlanta Biologicals, Lawrenceville, GA) and 0.1% Penicillin/Streptomycin 
(Sigma-Aldrich, St. Louis, MO).  For uptake experiments, stably expressing WT and 
IGLF DAT cells were split into poly D-lysine-coated 12-well plates (Becton-Dickinson, 
Bedford, MA) at a density of 2.0 X 10
5
 cells per well and used two days later.   
 
Stable transfections 
 HEK 293 cells were stably transfected with IGLF human dopamine transporter 
cDNA.  This construct was obtained from glycerol stocks (Waggoner Center for Alcohol 
and Addiction Research, University of Texas at Austin) using a Maxi prep kit (QIAGEN) 
and contained enhanced green fluorescent protein (eGFP) which allowed expressing cells 
to be identified by their green fluorescent glow.  HEK cells were transfected with 20 ug 
cDNA and 192 ul Polyfect transfection agent (QIAGEN), and selected using 0.6 mg/ml 
G418 antibiotic (Sigma-Aldrich) until cells were expressing protein in 80-90 % of cells 
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based on fluorescent readings.  Cells were treated with 0.3 mg/ml G418 whenever a 
change of media was required in order to prevent the proliferation of non-expressing cells.   
GFP labeled wild type (WT) DAT expressing HEK 293 cells were obtained from active 




H]DA uptake assays 
 WT and IGLF DAT expressing HEK 293 cells were plated in 12-well poly d-
lysine coated plates and incubated for two days at 37 degrees Celsius and 5% CO
2
.  The 
cells were washed with serum and antibiotic free DMEM .  After letting cells acclimate to 
25 degree Celsius temperature for 20 min in an incubator, half of the WT and IGLF cells 
(3 wells each) were treated with 10 uM 3-hydroxyphenyl N-propyl piperidine (Sigma-
Aldrich), a cocaine analog that blocks DAT action, to define nonspecific uptake.  100 nM 
[
3
H]DA was added to each for a 3-min time period.   
The cells were washed three times with Krebs-Ringer-HEPES (KRH) buffer (120 
mM NaCl, 4.7 mM KCl, 2.2 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 10 mM 
HEPES, pH 7.4) before being lysed in 500 ul of 1% sodium decyl sulfate (SDS) for 20 
minutes at room temperature with gentle shaking.  The lysates were used to quantify 
[
3
H]DA uptake for each condition using a liquid scintillation counter.       
 
  
Cell surface biotinylation 
 HEK 293 cells stably expressing WT and IGLF DAT were grown to 85-90% 
confluency in two T-150 culture flasks.  The cells were washed twice with ice cold 
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phosphate buffer saline , pH 7.4 (Gibco) supplemented with 0.1 mM CaCl2 and 1 mM 
MgCl2 (PBS/Mg/Ca),  and incubated with 10 ml of 1.0 mg/ml sulfosuccinimidyl-2-
(biotinamido)ethyl-1,2-dithiopropionate (EZ-link Sulfo-NHS-SS-Biotin) (Pierce, 
Rockford, IL) for 30 min at 4 degrees Celsius.  Excess biotin was quenched with two 
washes of ice cold PBS/Ca/Mg supplemented with 100-mM glycine, followed by two 
additional washes with ice cold PBS/Ca/Mg.  Biotinylated cells were scraped into the 
final wash, collected by centrifugation at 500g for 5 min, broken by ultrasound 
sonification, and lysed in 0.5 ml radioimmunoprecipitation assay buffer (150 mM NaCl, 
10 mM Tris, pH 7.2, 0.1% SDS, 1.0% Triton X-100, 1%deoxycholate, 5 mM EDTA, and 
protease inhibitor cocktail) for 30 min on ice with intermittent agitation.  The lysate was 
cleared of insoluble material by centrifugation at 12,000g for 10 min at 4 degrees Celsius, 
and 1:10 aliquot of the lysate was reserved to be analyzed later as total protein sample 
(total).  Sample (50 uL ) was added to 200 uL of Streptavidin coated Dynabeads 
(Invitrogen, Carlsbad, CA) at 4 degrees Celsius to separate biotinylated (cell surface) 
from nonbiotinylated (intracellular) proteins via affinity chromatography.  
Unbound proteins were removed by 1,000g centrifugation at 4 degrees Celsius for 
2 min.  After three washes with PBS, pH 7.4, the beads were incubated with 2X Laemmli 
buffer for 1 h at room temperature while rocking to elute biotinylated (cell surface) 
proteins bound to Dynabeads.  The protein concentration of the lysates was determined 
using DC Protein Assay kit (Bio-Rad, Hercules, CA), and an equal amount of protein was 
separated by SDS-PAGE in a 7.5% Tris-HCl Ready gel (Bio-Rad).  After the proteins 
were transferred to polyvinylidene difluoride (PVDF) membrane, the blots were blocked 
overnight at 4 degrees Celsius in Tris-buffered saline (TBS-T) (10 mM Tris-Cl, pH 8, 
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150 mM NaCl, 0.01% Tween-20) containing 5% nonfat dried milk (Bio-Rad).  Dopamine 
transporter was detected with a rat monoclonal antibody specific for the N-terminus of 
DAT (MAB 369, Millipore-Chemicon, Billeria, MA) for 2 h at room temperature while 
rocking in TBS-T containing 1% nonfat dried milk and 1% bovine serum albumin.  After 
three 10 min washes in TBS-T, blots were visualized by incubating blots in horseradish 
peroxidase conjugated rat secondary antibody (Santa Cruz Biotechnology, Sant Cruz, CA) 
for 1 h at room temperature and exposing to enhanced chemiluminescence solution 
(Perkin Elmer, Boston, MA).  Immunoreactivity was detected using a Kodak Image 
Station 2000 mm, and band intensities were quantified with NIH Image J software.   
 
Data analysis 
 Specific [3H]DAuptake was calculated as the difference between total and 
nonspecific uptake.  DAT surface densities were determined by quantifying the optical 
densities (ODs) from the Western analysis of cell surface and total populations of the 
transporter.  The relative amount of surface DAT was calculated by normalizing surface 
population ODs to their respective total population ODs of the transporter to obtain a 
ratio of surface expression.  The student’s t-test was used to compare WT to IGLF 













Figure 3.  IGLF DAT cells show no uptake of [3H] dopamine. 
  
As shown above in Figure 3, IGLF DAT expressing HEK 293 cells showed no 
specific uptake of [3H]DA, while WT DAT expressing HEK 293 cells demonstrated 
uptake capability (WT, 107.040 pmol/ml/min, S.E.M 20.697 pmol/ml/min; IGLF, -0.224 































Figure 4.  Surface Expression of WT DAT vs. IGLF DAT in HEK Cells as measured in 
percent of total protein on the surface.  
. 
  
The biotinylation assays confirmed the presence of IGLF DAT on the surface of 
HEK 293 cells.  Although the mean of IGLF DAT relative surface expression was lower 
than  that of WT DAT, they were not significantly different from one another (WT, 






























 Prior to this study, the working hypothesis was that IGLF was unable to take up 
dopamine due to lack of expression on the cell surface.  Lack of surface expression was 
demonstrated in Xenopus oocytes by performing radioactive WIN 35,428 binding assays 
(Maiya, et al., 2002).  These experiments quantified the surface expression levels of DAT 
by exposing WT and IGLF DAT expressing cells to [3H]WIN 35,428 which binds to the 
protein at the dopamine binding site.  This means that it shows the amount of surface 
DAT that has an exposed binding site.   However, our results in HEK 293 cells showed 
that the IGLF mutant was indeed expressed on the surface; and, in fact, the expression 
level was not significantly different from WT DAT.  The lack of uptake ability was 
conserved between the two model systems.   
 It is possible that this quadruple mutant could cause a structural change that 
obstructs one of the areas that are associated with substrate translocation (TMD 4 through 
8) (Buck and Amara, 1995).  Earlier studies dismissed large scale misfolding as a 
possible explanation by using antibodies that can bind to different regions of DAT (anti-
GFP instead of MAB 369) by showing that surface and total expression levels did not 
change between the two antibodies (Bjornstal, unpublished data).  However, both of the 
antibodies that were used bind to large, relatively isolated regions of the transporter such 
as the intracellular C-terminus, so we cannot rule out the possibility of smaller scale 
protein misfolding as causing the lack of function.  If the DA translocation domain was 
disrupted by this mutation, then the disparity between the [
3
H]WIN 35,428 binding assay 
data and these results could be reconciled.  For if this TMD 4 through 8 region were 
disrupted, the WIN 35,428 could not bind at all, so the results would seem to imply that 
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there was no IGLF on the surface, whereas our biotinylation assay more directly 
measures the surface levels.     
    It would be interesting to determine if DAT mutant shows any concentration 
dependent trafficking by ethanol like WT DAT (Riherd et al., 2008).  If so, the fact that 
ethanol does not enhance G130T activity would further complicate the issue (as the 
G130T mutation is contained in the IGLF construct).  This could be easily tested by 
incubating the WT and IGLF DAT expressing HEK 293 cells in graded concentrations of 
ethanol prior to biotinylation.  Also, testing IGLF DAT’s ability to take up 
norepinephrine, which is readily taken up by WT DAT might help to determine if IGLF 
really has a disrupted binding site.  If significant NE transport takes place, then it is less 
likely that a folding error is the problem, as it is unlikely the mutation would make the 
TMD 4 through 8 region amenable to uptake of a different catecholamine.   
 Although IGLF DAT is trafficked to and stably expressed on the surface of HEK 
293 cells in quantities not significantly different from those of WT DAT, in order to 
determine the mechanism behind this, further tests need to be completed.  The hypothesis 
that misfolding of the TMD 4 through 8 region, which has been implicated in dopamine 
and norepinephrine translocation, could be further elucidated by testing IGLF DAT 
expressing cells’ ability to take up [
3
H]NE, while testing whether surface expression is 
potentiated by the addition of ethanol could help us to understand the puzzling fact that a 
quadruple mutant (IGLF) containing a single mutation (G130T) with a functionally 
significant phenotype would lack said phenotype.    
 In conclusion, this study set out to determine the location of the nonfunctional 
quadruple mutant IGLF DAT and found that it was indeed present on the surface of HEK 
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293 cells.  Coupled with its lack of ability to translocate dopamine from the extracellular 
space, this implies that the mutant is “broken” in some way.  We have concluded that the 
most likely explanation is that the four amino acid changes making up this mutant 
misfold the protein in such a way as to obstruct the substrate binding site.  This explains 
the disparity between previous studies with WIN 35,428 and the present study’s cell 
surface biotinylation results. 
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